FDA-approved for obesity — the highest weight-loss drug ever tested. Complete guide.
Zepbound (tirzepatide) is a once-weekly injectable medication FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. It is made by Eli Lilly and is the weight-loss-approved version of Mounjaro — they contain the same active ingredient at the same doses.
Zepbound is the most powerful weight-loss drug ever approved by the FDA. The SURMOUNT-1 clinical trial showed average weight loss of 20.9% at the 15mg dose — a result that stunned the medical community and led to tirzepatide being called a "paradigm shift" in obesity treatment.
All other approved GLP-1 drugs (Ozempic, Wegovy) only activate the GLP-1 receptor. Zepbound activates two receptors simultaneously:
Reduces appetite, slows gastric emptying, controls blood sugar — same as Ozempic and Wegovy.
Further amplifies insulin secretion, reduces fat storage in adipose tissue, improves energy expenditure, works synergistically with GLP-1.
The dual activation is why tirzepatide produces dramatically more weight loss than semaglutide — it's not just a stronger dose of the same thing, it's a fundamentally different mechanism.
Zepbound follows the same 6-step titration as Mounjaro. The gradual escalation is essential — rushing doses causes significantly more nausea and GI side effects.
Side effects mirror Mounjaro since they're the same drug. GI effects are most common and typically peak during dose escalation, improving significantly after reaching your maintenance dose.
| Scenario | Monthly Cost |
|---|---|
| List price | ~$1,059 |
| Commercial insurance (obesity indication) | Varies — often $0–$550 |
| Eli Lilly savings card (commercially insured, eligible) | ~$25–$550/mo |
| Medicare Part D (2026) | ~$150–$300/mo (est.) |
| No insurance / not eligible for savings | ~$1,059/mo |
| Lilly patient assistance (low income) | $0 (if eligible) |
The SURMOUNT-5 trial (2025) finally gave us a direct comparison. Here's what the data says:
| Factor | Zepbound | Wegovy |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide |
| Mechanism | GLP-1 + GIP (dual) | GLP-1 only |
| SURMOUNT-5 Weight Loss | ~20% (winner) | ~14% |
| Heart Disease Data | ⏳ Trial ongoing | ✅ Proven (SELECT) |
| List Price | ~$1,059 | ~$1,349 |
| Self-Pay Option | ✅ Vials from $399/mo | ❌ No equivalent |
| Best for | Max weight loss, cost-conscious | Proven heart protection |
Bottom line: Zepbound wins on weight loss efficacy and cost. Wegovy wins if you have existing cardiovascular disease and need proven heart protection data. For most obesity patients without established heart disease, Zepbound is currently the top choice.
Yes — identical drug, same doses, same manufacturer. The only difference is the FDA approval and insurance coverage pathway:
Different drug entirely. Ozempic contains semaglutide and only activates GLP-1 receptors. Zepbound contains tirzepatide and activates both GLP-1 and GIP receptors. The dual mechanism produces significantly more weight loss — about 20% vs 15% on average. Ozempic is approved for diabetes; Zepbound is approved for obesity.
Nausea rates are similar in clinical trials — approximately 44% in both. However, some patients report that tirzepatide's nausea feels slightly different. The key is the same: slow titration, smaller meals, avoiding greasy foods, and staying hydrated dramatically reduces GI side effects on both drugs.
Starting in 2026, Medicare Part D plans can cover GLP-1 medications including Zepbound for obesity. Prior authorization is typically required. Coverage varies by plan — call your plan directly and ask about Zepbound coverage and the formulary tier.
In late 2024, Eli Lilly introduced Zepbound in single-dose vials sold through LillyDirect (their direct-to-patient pharmacy) at $399–$549/month depending on dose — significantly cheaper than list price. These require a prescription but are self-pay (not run through insurance). A major option for uninsured or underinsured patients.
Like all GLP-1 drugs, stopping Zepbound typically results in weight regain. Studies show most patients regain the majority of lost weight within 1–2 years of stopping. The drug treats a chronic biological condition — stopping it is similar to stopping blood pressure medication. Your doctor should help you plan a long-term strategy.